Food and Drug Administration

Cardiovascular and Renal Drugs Advisory Committee

June 16, 2005

Briefing Information

NitroMed, Inc.

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

NitroMed, Inc., BiDil® (Isosorbide Dinitararte and Hydralazine Hydrochloride) Tablets Briefing Information
[HTML]  [PDF]

FDA

Disclaimer

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. §552). 
These redacted portions will appear as white space on the screen or on the printed page.

FDA Table of Contents